Herceptin is a monoclonal antibody commonly used as a first-line treatment in HER2+ breast cancer, including IBC, where approximately 50% of cases are HER2+ compared with 25% in non-IBC breast cancer [17]. Here, ERBB2 is linked to inflammatory breast carcinoma.